(Tafluprost + timolol maleate) is a Small Molecule owned by Santen Pharmaceutical, and is involved in 19 clinical trials, of which 16 were completed, and 3 are ongoing.

Tafluprost acts as a prostanoid selective F2-alpha receptor agonist. It reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humor. It specifically binds at sites of prostaglandin F2 alpha which are co-localised at high levels in the areas of the ciliary muscles and iris sphincter muscles and at  lower levels in the iris epithelium and the retina.

Timolol is a non-selective beta-adrenergic antagonist with antihypertensive property. Timolol competitively binds to beta-1-adrenergic receptors in the heart and vascular smooth muscle and beta-2-receptors in the bronchial and vascular smooth muscle, resulting in a decrease in beta-adrenergic stimulation. Beta-1-receptor blockade results in a decrease in resting and exercise heart rate and cardiac output, a decrease in both systolic and diastolic blood pressure, and, possibly, a reduction in reflex orthostatic hypotension. Beta-2-blockade results in an increase in peripheral vascular resistance. The ultimate results include vasodilation, and negative chronotropic and inotropic effects. In addition, timolol reduces intra-ocular pressure possibly by decreasing aqueous humor production by reduction of blood flow to the ciliary processes and cAMP synthesis.

The revenue for (Tafluprost + timolol maleate) is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Tafluprost + timolol maleate) NPV Report.

(Tafluprost + timolol maleate) is currently owned by Santen Pharmaceutical.

(Tafluprost + timolol maleate) Overview

Tafluprost and timolol maleate (Tapcom / Taptiqom /Loyada / Taptiqom Sine) is a fixed dose combination, acts as anti-glaucoma agent. It is formulated as drops solution for ophthalmic administration. It is indicated for the treatment of glaucoma or open-angle glaucoma and ocular hypertension.

A fixed dose combination of tafluprost and timolol maleate (Tapcom/ Taptiqom) is under development for the treatment of open-angle glaucoma and ocular hypertension in China. The drug candidate is administered through ophthalmic route as drops.

Santen Pharmaceutical Overview

Santen Pharmaceutical (Santen) focuses on the research, development, manufacturing and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation, cataract, muscae volitantes, diabetic retinopathy, retinal detachment, hyposphagma, myopia, retinal detachment, amblyopia, astigmatism, strabismus, hordeolum, VDT syndrome and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through its group companies located in Asia, Europe and the US. It operates production facilities in Noto, and Shiga, Japan; and Suzhou, China. Santen is headquartered in Kita-ku, Osaka, Japan.

The company reported revenues of (Yen) JPY266,257 million for the fiscal year ended March 2022 (FY2022), an increase of 6.7% over FY2021. In FY2022, the company’s operating margin was 14%, compared to an operating margin of 4.9% in FY2021. In FY2022, the company recorded a net margin of 10.2%, compared to a net margin of 3.7% in FY2021. The company reported revenues of JPY63,382 million for the second quarter ended September 2022, a decrease of 3.3% over the previous quarter.

Quick View – (Tafluprost + timolol maleate)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Tafluprost + timolol maleate)
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.